ATB0,+ transporter-mediated targeting delivery to human lung cancer cells via aspartate-modified docetaxel-loading stealth liposomes (original) (raw)
* Corresponding authors
a School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
E-mail: sunjin66@21cn.com, chexin98@aliyun.com
Fax: +86-24-23986321
Tel: +86-24-23986321
b Department of Pharmacy, the First Affiliated Hospital of China Medical University, Shenyang, China
c School of Pharmaceutical Science, China Medical University, Shenyang 110122, China
d College of life science and biological pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
e Department of Biomedical Engineering, School of Medical Devices, Shenyang Pharmaceutical University, Shenyang, China
f Municipal Key Laboratory of Biopharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
Abstract
Tumor cells have an increased demand for amino acids to support their rapid growth and malignant metastasis. Transfer of amino acids across plasma membranes depends on several amino acid transporters that are highly upregulated in tumor cells and are promising targets for tumor cell-selective therapy. In this study, stealth liposomal systems functionalized with aspartate-polyoxyethylene stearate conjugate (APS) were developed for transporter-mediated targeted delivery to ATB0,+, which is overexpressed human lung cells. The resultant ATB0,+-targeting liposomes (APS-Lips) consisted of a liposome core and the surface coverage of the APS modifier had an optimized density of 10%. APS-Lips had a uniform particle size distribution and high encapsulation efficiency of docetaxel (DTX, >80%). APS modification had a negligible effect on the DTX release from liposomes. Compared with Taxotere and unmodified liposomes, APS-Lips showed increased intracellular delivery and antitumor potency against human lung cells. Furthermore, competitive endocytosis studies showed that the cellular uptake of APS-Lips was notably decreased in the presence of glycine, a typical substrate of ATB0,+, and was increased through adhesion to the cell membrane via transporter-substrate interactions. Finally, in vitro hemolysis and in vivo vascular irritation studies in rabbits confirmed the good blood compatibility and minimal vascular stimulation of the synthetic ATB0,+-targeting material APS. These results demonstrated that the aspartate-modified liposomes could be a promising nanocarrier for ATB0,+ transporter-mediated targeted drug delivery to treat lung cancer.
You have access to this article
Please wait while we load your content... Something went wrong. Try again?
Article information
DOI
https://doi.org/10.1039/C6BM00788K
Article type
Paper
Submitted
05 Nov 2016
Accepted
29 Nov 2016
First published
19 Dec 2016
Download Citation
Biomater. Sci., 2017,5, 295-304
Permissions
ATB0,+ transporter-mediated targeting delivery to human lung cancer cells via aspartate-modified docetaxel-loading stealth liposomes
Q. Luo, B. Yang, W. Tao, J. Li, L. Kou, H. Lian, X. Che, Z. He and J. Sun,Biomater. Sci., 2017, 5, 295DOI: 10.1039/C6BM00788K
To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.